^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD20 positive

    i
    Other names: CD20, MS4A1, Membrane Spanning 4-Domains A1, Membrane-Spanning 4-Domains, Subfamily A, Member 1, Leukocyte Surface Antigen Leu-16, B-Lymphocyte Antigen CD20, CD20 Antigen, Membrane-Spanning 4-Domains Subfamily A Member 1, B-Lymphocyte Cell-Surface Antigen B1, B-Lymphocyte Surface Antigen B1, CD20 Receptor, LEU-16, CVID5, MS4A2
    Entrez ID:
    494216
    Related biomarkers:
    Expression
    Others
    3d
    Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Mwanasha Merrill, MD
    New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • dexamethasone • Epkinly (epcoritamab-bysp)
    3d
    GLOHRT-01: Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden (clinicaltrials.gov)
    P2, N=40, Recruiting, Liling Zhang | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
    |
    CD20 positive
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    5d
    ZGR in TN FL: Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma (clinicaltrials.gov)
    P2, N=34, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    lenalidomide • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib)
    6d
    Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (clinicaltrials.gov)
    P2, N=99, Active, not recruiting, Christian Buske | Trial completion date: Aug 2028 --> May 2028 | Trial primary completion date: Aug 2028 --> May 2028
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    CD20 positive
    |
    Imbruvica (ibrutinib) • carfilzomib
    7d
    Progressive Pulmonary Lesions and Cervical Lymphadenopathy Revealing Large B-cell Lymphoma: A Rare Case Report. (PubMed, Cureus)
    A repeat lung biopsy ultimately confirmed DLBCL, with immunohistochemistry positive for CD20 and negative for CD3 and cytokeratin. This case underscores the diagnostic complexity of primary extranodal DLBCL involving the lung and thyroid, highlights the limitations of initial tissue sampling, and emphasizes the importance of persistent diagnostic evaluation and multidisciplinary collaboration when clinical suspicion remains high.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    7d
    Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)
    7d
    The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk (clinicaltrials.gov)
    P3, N=640, Recruiting, Ruijin Hospital | Trial completion date: Sep 2025 --> Jun 2028 | Trial primary completion date: Sep 2025 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide
    9d
    POLARIX: A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=1000, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed
    Trial completion
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    ALK positive • CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Polivy (polatuzumab vedotin-piiq)
    12d
    Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=0, Withdrawn, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | N=20 --> 0 | Trial completion date: Dec 2028 --> Jan 2027 | Recruiting --> Withdrawn
    Enrollment change • Trial completion date • Trial withdrawal
    |
    CD22 (CD22 Molecule)
    |
    CD20 positive • CD20 negative
    |
    cyclophosphamide • fludarabine IV
    12d
    Splenic Marginal Zone Lymphoma as a Vascular-Appearing Mass in a Patient With Sustained Virologic Response to Hepatitis C Therapy. (PubMed, Am J Case Rep)
    Tumor infarction and slow organization can produce radiologic features that mimic vascular splenic lesions. This demonstrates the importance of clinicoradiological-pathological correlation and the necessity of histological confirmation in indeterminate splenic masses to avoid delays in management.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    13d
    QUILT-106: Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=10, Recruiting, ImmunityBio, Inc. | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    CD20 positive
    |
    Rituxan (rituximab) • CD19.t-haNK
    14d
    RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive